Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortizatization of Intangibles (2023 - 2025)

Historic Amortizatization of Intangibles for Ani Pharmaceuticals (ANIP) over the last 4 years, with Q3 2025 value amounting to $358000.0.

  • Ani Pharmaceuticals' Amortizatization of Intangibles fell 8552.95% to $358000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 22119.28%. This contributed to the annual value of $13.6 million for FY2024, which is 97163.12% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Amortizatization of Intangibles stood at $358000.0, which was down 8552.95% from $394000.0 recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Amortizatization of Intangibles peaked at $10.4 million during Q4 2024, and registered a low of $61000.0 during Q2 2023.
  • Its 3-year average for Amortizatization of Intangibles is $1.6 million, with a median of $387500.0 in 2023.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 262309.71% in 2024, then tumbled by 8552.95% in 2025.
  • Over the past 3 years, Ani Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $381000.0 in 2023, then surged by 2623.1% to $10.4 million in 2024, then tumbled by 96.55% to $358000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $358000.0 for Q3 2025, versus $394000.0 for Q2 2025 and $452000.0 for Q1 2025.